Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail. However, the initiative is capital intensive. Worse yet, the trajectory is driven by probability rather than linear growth.In other words, years of research and billions in investments can hinge on a single clinical readout or regu ...